Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated With Concurrent Chemoradiation

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 1, 2008, Pages 199-204

  Choi, Chel Hun ^a   Kang, Heeseok ^a   Kim, Woo Young ^a   Kim, Tae Joong ^a   Lee, Jeong Won ^a   Huh, Seung Jae ^a   Lee, Je Ho ^a   Kim, Byoung Gie ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Baseline lymphocyte count; Concurrent chemoradiation; Locally advanced cervical carcinoma

Indexed keywords

CHEMOTHERAPY; GYNECOLOGY; HEALTH HAZARDS; MATHEMATICAL MODELS; PATIENT MONITORING; RADIOTHERAPY; TUMORS;

BASELINE LYMPHOCYTE COUNT; CONCURRENT CHEMORADIATION; LOCALLY ADVANCED CERVICAL CARCINOMA; PROGRESSION FREE SURVIVALS;

ONCOLOGY;

CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 41749106005     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.024     Document Type: Article

References (33)

1. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J Clin 49 31 (1999) 33-64
2. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
3. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
4. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
5. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
6. Sardi J., Sananes C., Giaroli A., et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 49 (1993) 156-165
7. Tierney J. Neoadjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39 (2003) 2470-2486
8. Gupta S, Tongaonkar HB, Shrivastava SK. A prospective randomized trial of neoadjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IIB squamous carcinoma of the uterine cervix. Available at: http://clinicaltrials.gov/ct/gui/show/NCT00193739?order=1. Accessed October 19, 2007.
9. Cannon G.B., Dean J.H., Herberman R.B., et al. Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer 25 (1980) 9-17
10. Check I.J., Hunter R.L., Karrison T., et al. Prognostic significance of immunological tests in lung cancer. Clin Exp Immunol 43 (1981) 362-369
11. Kagi D., Ledermann B., Burki K., et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369 (1994) 31-37
12. Kagi D., Ledermann B., Burki K., et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14 (1996) 207-232
13. Korner H., and Sedgwick J.D. Tumour necrosis factor and lymphotoxin: Molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 74 (1996) 465-472
14. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
15. Shu S., Plautz G.E., Krauss J.C., et al. Tumor immunology. JAMA 278 (1997) 1972-1981
16. Riesco A. Five-year cancer cure: Relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25 (1970) 135-140
17. Kim U.S., Papatestas A.E., and Aufses Jr. A.H. Prognostic significance of peripheral lymphocyte counts and carcinoembryonic antigens in colorectal carcinoma. J Surg Oncol 8 (1976) 257-262
18. Lavin P.T., Bruckner H.W., and Plaxe S.C. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 50 (1982) 2016-2023
19. International Commission on Radiation Units and Measurements. Report 38, Dose and Volume Specifications for Reporting Intracavitary Therapy in Gynecology (1985), International Commission in Radiation Units and Measurements, Bethesda, MD
20. Choi C.H., Kim T.J., Lee J.W., et al. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol 104 (2006) 64-69
21. Higgins G.D., Davy M., Roder D., et al. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 338 (1991) 910-913
22. Riou G., Favre M., Jeannel D., et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 335 (1990) 1171-1174
23. Balaram P., Pillai M.R., Padmanabhan T.K., et al. Immune function in malignant cervical neoplasia: A multiparameter analysis. Gynecol Oncol 31 (1988) 409-423
24. Radhakrishna Pillai M., Balaram P., Chidambaram S., et al. Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia. Gynecol Oncol 37 (1990) 200-205
25. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 (1980) 25-32
26. Santin A.D., Hermonat P.L., Ravaggi A., et al. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 48 (2000) 997-1006
27. Santin A.D., Hermonat P.L., Hiserodt J.C., et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys 39 (1997) 737-742
28. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
29. Hashimoto S. [Effects of low-dose total body irradiation (TBI) on tumor-bearing rats]. Nippon Igaku Hoshasen Gakkai Zasshi 57 (1997) 418-424
30. Hashimoto S., Shirato H., Hosokawa M., et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res 151 (1999) 717-724
31. Thomas G.M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 340 (1999) 1198-1200
32. Cavallo F., Signorelli P., Giovarelli M., et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89 (1997) 1049-1058
33. de Gast G.C., Klumpen H.J., Vyth-Dreese F.A., et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6 (2000) 1267-1272